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ABSTRACT 27 
The most widespread form of malaria is caused by Plasmodium vivax.  To replicate, this parasite 28 
must invade immature red blood cells, through a process which requires interaction of the 29 
Plasmodium vivax Duffy binding protein, PvDBP with its human receptor, the Duffy antigen receptor 30 
for chemokines, DARC. Naturally acquired antibodies that inhibit this interaction associate with 31 
clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent 32 
malaria due to Plasmodium vivax. Here, we isolated a panel of monoclonal antibodies from human 33 
volunteers immunised in the first clinical vaccine trial of PvDBP. We screened their ability to prevent 34 
PvDBP from binding to DARC, and their capacity to block red blood cell invasion by a transgenic 35 
Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte 36 
invasion by multiple clinical isolates of Plasmodium vivax. This identified a broadly neutralising 37 
human monoclonal antibody which inhibited invasion of all tested strains of Plasmodium vivax. 38 
Finally, we determined the structure of a complex of this antibody bound to PvDBP, revealing the 39 
molecular basis for inhibition. These findings will guide future vaccine design strategies and open up 40 
possibilities for testing the prophylactic use of such an antibody.  41 
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INTRODUCTION  42 
In large parts of the world, Plasmodium vivax is the dominant species causing human malaria [1, 2]. 43 
An effective blood-stage vaccine would reduce morbidity, lower blood-stage asexual and sexual 44 
parasite densities and aid progress towards elimination. The symptoms of malaria occur as the 45 
parasites invade, replicate within and burst out of the red blood cells (RBC) of infected individuals. 46 
Plasmodium vivax parasites invade immature RBC, selecting reticulocytes that express the 47 
transferrin receptor CD71 [3, 4]. Important in this invasion process is the parasite surface protein, 48 
Plasmodium vivax Duffy-binding protein, PvDBP, which interacts with the Duffy antigen receptor for 49 
chemokines, DARC/Fy, on the surface of reticulocytes, in a process essential for invasion [5, 6]. 50 
Consistent with this, genetic knockout of the orthologous DBPα gene from the closely-related simian 51 
malaria Plasmodium knowlesi also prevents invasion of Duffy-positive erythrocytes in vitro [7] and 52 
antibodies that target PkDBP can block invasion of RBC by Plasmodium knowlesi [8]. Moreover, a 53 
human polymorphism which results in Duffy-negative erythrocytes [9] is widespread across Africa 54 
and is associated with protection from Plasmodium vivax infection [10]. This leads to low levels of 55 
vivax-malaria across much of the continent [11] and highlights PvDBP as the most promising 56 
candidate for inclusion in a vaccine to prevent Plasmodium vivax [12]. 57 
 58 
PvDBP has been divided into six distinct regions, with the DARC binding site mapped to a ~350 amino 59 
acid residue domain known as Region II, PvDBPII, which takes the form of a Duffy-binding-like (DBL) 60 
domain [6]. The first structure of a DBL domain was that from the P. knowlesi orthologue of PvDBPII 61 
[5] and was split into three regions, known as subdomains 1-3 [5]. PvDBPII binds to the sixty-residue 62 
extracellular N-terminal ectodomain of DARC, in an interaction which requires DARC to be post-63 
translationally modified by sulphation of two tyrosine residues, Tyr30 and Try41 [13, 14]. 64 
Nevertheless, the interaction between PvDBPII and DARC is only partially understood. Structural 65 
studies of PvDBPII show the domain to form dimers in both solution and in a crystal [13]. In addition, 66 
structures of PvDBPII crystallised in the presence of the ectodomain of DARC, reveal an ordered 11-67 
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residue helical peptide (DARC19-30), which lies close to the PvDBPII dimer interface in subdomain 2 68 
[15]. However, the DARC protein used in these studies was not tyrosine-sulphated and sulphated 69 
Tyr41, which cannot be seen in this study, was previously shown to be essential for high affinity 70 
PvDBPII binding [14]. Indeed, mapping residues identified by mutagenesis onto the structure of 71 
PvDBPII reveals an additional patch on subdomain 2 proposed to contribute to DARC binding [16, 17] 72 
and it is likely that the DARC binding site spans much of the surface of subdomain 2 and includes 73 
both this patch and the region that interacts with the helical DARC19-30 peptide.  74 
 75 
Development of PvDBPII-based vaccine candidates has progressed through pre-clinical studies to the 76 
first Phase I human clinical trials, both recently reported [18, 19]. Immunisation of mice, rabbits and 77 
non-human primates using PvDBPII-based vaccines induces the production of inhibitory antibodies 78 
that block recombinant PvDBPII:DARC in vitro binding [20, 21]. However, challenges in sustaining 79 
Plasmodium vivax in long-term culture [22] have prevented these antibodies from being robustly 80 
tested in standardised functional growth inhibition assays, as is traditionally performed for vaccines 81 
targeting Plasmodium falciparum [12]. Nevertheless, in humans, the presence of high-titres of 82 
naturally-acquired antibodies that target PvDBPII and prevent DARC binding in vitro are associated 83 
with reduced risk of Plasmodium vivax infection [23], as well as lower parasite densities following 84 
invasion and decreased risk of clinical malaria [24, 25]. Encouragingly, in a recent Phase Ia clinical 85 
trial, immunisation of human volunteers using recombinant viral vectors expressing PvDBPII induced 86 
strain-transcending antibodies which prevented recombinant PvDBPII from binding to DARC [19], 87 
confirming for the first time that such antibodies could be raised by human vaccination.  88 
 89 
Several studies have investigated the molecular basis for antibody-mediated inhibition of DARC 90 
binding by PvDBPII [13, 15, 26, 27]. Screening a linear peptide array with non-inhibitory and 91 
inhibitory human serum has identified peptides which recognise antibodies found specifically in 92 
inhibitory serum [27]. These peptides are located within subdomain 2, in the regions involved in 93 
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PvDBPII dimerisation and DARC19-30 peptide binding [15]. These data suggest that antibodies which 94 
directly block dimerisation and DARC binding are desirable. In addition, a study of monoclonal 95 
antibodies (mAbs) derived from PvDBPII-immunised mice used structural studies and mass-96 
spectrometry based mapping approaches to identify three epitopes for antibodies shown to block 97 
DARC binding in vitro [26]. Surprisingly, these epitopes are located on subdomain 3 of PvDBPII, 98 
distant from the DARC binding site. 99 
 100 
In order to understand the epitopes for human inhibitory antibodies, and to guide future structure-101 
guided immunogen development, we have now cloned a panel of antibodies from PvDBPII 102 
immunised human volunteers. We have determined their ability to inhibit the binding of 103 
recombinant PvDBPII to DARC in vitro, as well as their capacity to neutralise parasite invasion in two 104 
distinct parasite-based functional assays. Our data provide important insight into these different in 105 
vitro readouts of antibody function and, furthermore, have led to the structural characterisation of 106 
an epitope for an antibody that shows broadly neutralising activity against parasite invasion. 107 
  108 
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RESULTS 109 
Cloning of a panel of vaccine-induced human monoclonal antibodies that bind to 110 
PvDBPII 111 
Anti-PvDBPII mAbs were isolated from the antibody-secreting cells of immunised volunteers enrolled 112 
in a first-in-human Phase Ia clinical trial of a PvDBPII-based vaccine delivered using recombinant 113 
chimpanzee adenovirus and poxvirus viral vectors [19]. Variable region (VR)-coding genes were 114 
isolated by RT-PCR and PCR and cloned into a human IgG1 scaffold. Cognate heavy-chain and light-115 
chain plasmids were expressed together in HEK293 cells and vaccine antigen-specificity was 116 
confirmed by supernatant reactivity to a PvDBPII protein comprising amino acids D194 to T521. 117 
 118 
Ten genetically distinct mAbs were isolated (Table S1). Aligning them with the most similar germline 119 
VR genes in IgBLAST [28] showed little non-germline sequence, suggesting the viral vectored vaccine 120 
regimen drives minimal somatic hypermutation in humans. The monovalent binding affinity of each 121 
mAb was assessed by surface plasmon resonance (SPR) (Figure 1A-D and Table S2). Affinities were in 122 
the low nanomolar to high picomolar range, likely owing to the use of a stringent ELISA selection 123 
process during mAb isolation. 124 
 125 
To understand the relationship between binding site and function, mAbs were tested in pairs for 126 
their ability to bind simultaneously to biotinylated PvDBPII by Biolayer Interferometry (BLI) (Figure 127 
1E,F). This defined two distinct epitope bins containing mAbs which bind overlapping epitopes, as 128 
well as three mAbs with distinct non-overlapping epitopes (Figure 1G). 129 
 130 
To characterise the ability of the human mAbs to inhibit binding of PvDBPII to DARC, they were 131 
tested in vitro in an ELISA-based binding inhibition assay [29]. The effect of PvDBPII polymorphism 132 
on mAb recognition was assessed by testing their effect on the binding of the N-terminal DARC 133 
ectodomain to a panel of five sequence-divergent PvDBPII proteins [19] (Figure 2, Figure S1). Most 134 
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mAbs showed differential binding inhibition, with only two (DB2 and DB9) inhibiting the DARC 135 
binding of all five PvDBPII variant alleles (Figure 2). 136 
 137 
Assessing the neutralisation of parasite invasion by the antibody panel 138 
To characterise the ability of the human mAbs to block merozoite entry into RBC, assays of growth 139 
inhibition activity (GIA) were performed. A novel Plasmodium knowlesi line was used that has been 140 
adapted to long-term in vitro culture in human RBC [30] and in which the native PkDBPα gene had 141 
been replaced by the PvDBP gene (Mohring F et al., submitted). Plasmodium knowlesi is also 142 
dependent on the DARC receptor for RBC invasion, but unlike Plasmodium vivax, it has three DBP 143 
genes; PkDBPα, PkDBPβ and PkDBPγ [31]. PkDBPβ and PkDBPγ are thought to be required for 144 
invasion of rhesus RBC whereas PkDBPα is essential for invasion of human RBC [7, 32, 33]. The ten 145 
mAbs were thus assayed for growth inhibition against five Plasmodium knowlesi lines: First, the 146 
original human-RBC adapted PkA1H1 strain [30]. Second, two transgenic PkA1H1 lines, PvDBPOR in 147 
which the PkDBPα gene had been replaced with the PvDBP gene (this transgenic insert was the full-148 
length PvDBP Salvador I (SalI) strain vaccine-homologous sequence), and PvDBPOR/Δβγ in which the 149 
same gene swap had taken place and additionally the native PkDBPβ and PkDBPγ genes had been 150 
deleted. This PvDBPOR/Δβγ line was considered the best model for Plasmodium vivax as the only DBP 151 
gene present in the parasite was the PvDBP gene. Finally, there were also two transgenic control 152 
lines, PkDBPαOR and PkDBPαOR/Δβγ in which the native PkDBP genes had been deleted and replaced 153 
with re-codonised versions of themselves.  154 
 155 
Only one of the anti-PvDBPII mAbs, DB7, at high concentration, inhibited growth of the three P. 156 
knowlesi control lines (Figure 3A), suggesting an epitope cross-reactive with PkDBPα. In contrast, 157 
when assayed against the transgenic PvDBP-expressing Plasmodium knowlesi lines, three of the 158 
mAbs showed high levels of inhibition of parasite growth, with four showing intermediate levels and 159 
the remaining three showing modest activity; whilst a control human mAb against Ebolavirus 160 
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showed no detectable GIA (Figure 3A). The three most neutralising anti-PvDBPII mAbs in this assay 161 
(DB1, DB9 and DB10) had EC50 values comparable to mouse-derived mAbs which potently prevent 162 
erythrocyte invasion by Plasmodium falciparum [34, 35]. A strong correlation (P = 0.002, ρ=-0.951) 163 
was also observed between the association-rate (kon) of the mAbs and GIA (Figure 3B), indicating 164 
that the opportunity for PvDBP blockade in the context of merozoite invasion is likely to be time-165 
limited [35, 36]. In contrast, this panel of mAbs showed no correlation between GIA and either 166 
dissociation rate or affinity (Figure 3B). 167 
 168 
In addition, we tested the mAbs directly for their capacity to prevent reticulocyte invasion by 169 
Plasmodium vivax parasites derived from thirteen clinical isolates originating from Thai patients, 170 
using ex-vivo short-term culture invasion inhibition assays (Figure 4A). Sequencing of the PvDBPII 171 
gene region from eight of these isolates revealed significant polymorphism (Figure 4C). Some 172 
isolates had PvDBPII sequences identical to the SalI reference strain used in the vaccine (#4 and #7) 173 
while others were very polymorphic, with as many as ten amino acid substitutions in region II of the 174 
DBP gene (#6 and #8).  175 
 176 
These assays revealed marked strain-dependent differences in the potency of the anti-PvDBPII 177 
mAbs. For example, DB1 and DB10, the two most inhibitory mAbs in the transgenic Plasmodium 178 
knowlesi GIA assay (containing the SalI PvDBP transgene), inhibited invasion of the Thai isolates with 179 
the same SalI PvDBPII sequences (isolates #4 and #7) but not those with heterologous PvDBPII 180 
sequences (isolates #5 and #8) (Figure 4B,D). Notably, for these two Plasmodium vivax parasite 181 
isolates which possessed the homologous SalI PvDBPII sequence, the hierarchy of mAb potency also 182 
mirrored that observed in the transgenic Plasmodium knowlesi model (Figure 4B), suggesting this 183 
model is highly predictive of P. vivax neutralisation. Indeed, irrespective of some strain-dependence, 184 
mAbs DB3, 5, 6 and 7 showed intermediate median levels of inhibition (~40-60 %), whilst mAbs DB2, 185 
4 and 8 showed low median levels (~10-20 %). However, in contrast to these data, only one of the 186 
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ten mAbs (DB9) potently inhibited invasion (~65-90 %) of 10/11 of the isolates against which it was 187 
tested. DB9 had also shown potent growth inhibition in the transgenic P. knowlesi assays of GIA 188 
(Figure 3A) and inhibited binding of all 5 variant alleles of PvDBPII to DARC (Figure 2B), highlighting it 189 
as an antibody with broadly neutralising activity against a wide range of P. vivax variants.  190 
 191 
Antagonism of DB9-mediated inhibitory activity  192 
Having identified DB9 as a broadly neutralising mAb, we sought to assess whether its parasite-193 
neutralising effects would be enhanced or diminished by combining it with the other nine mAbs in 194 
the panel. The BLI binding-competition assay (Figure 1E-G), showed that half of the mAbs, including 195 
DB9, compete with each other for binding sites on recombinant PvDBPII. To test for evidence of 196 
synergy or antagonism [37] between DB9 and the other mAbs, we ran GIA assays using the PvDBPOR 197 
line of transgenic P. knowlesi in which DB9 was added at a fixed concentration of 25 μg/mL, together 198 
with a dilution series of one of the other nine mAbs (Figure 5). While no synergy was detected, there 199 
was apparent antagonism between DB9 and five of the other mAbs. Surprisingly, these were the five 200 
mAbs (DB1, DB4, DB5, DB7 and DB10) which did not compete with DB9 for binding to PvDBPII in the 201 
BLI competition assay (Figure 1E-G). In contrast, the other four mAbs (DB2, DB3, DB6 and DB8), 202 
which bound epitopes overlapping with that of DB9, showed an additive growth inhibitory effect 203 
with DB9 in this assay. These data suggest that antibodies that bind in and around the DB9 epitope 204 
are able to function in an independent and additive manner, whilst antibodies that bind to distinct 205 
epitope regions elsewhere on the PvDBPII molecule actively inhibit each other’s functional activity. 206 
Given DB9 was able to show strain-transcending high-level neutralising activity, this raised the 207 
imperative to understand the epitope of DB9 and thus enable the future design of immunogens 208 
which specifically induce DB9-like antibodies. 209 
 210 
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The molecular basis for the action of DB9  211 
To determine how DB9 binds to PvDBPII, we produced a construct containing residues 211-508 of 212 
PvDBPII by refolding material expressed in E. coli. This was mixed with Fab fragments of DB9 and the 213 
complex was crystallised. Crystals diffracted to 3.0 Å resolution, allowing structure determination by 214 
molecular replacement (Figure 6 and Table S3). A comparison of the structure of PvDBPII in complex 215 
with DB9 with that of un-liganded PvDBPII revealed no change in PvDBPII conformation (with an 216 
RMSD of 0.523Å). 217 
 218 
The epitope of DB9 is contained solely within subdomain 3 of PvDBPII (Figure 6A). This region 219 
consists of two long α-helices (H1 and H2), which form a platform on which three small helices (H3-220 
H5) and their intervening loops are arranged (Figure S2). All three CDR loops of the heavy chain and 221 
CDR1 and CDR2 of the light chain directly contact PvDBPII (Figure S2 and Table S4). The epitope 222 
includes a single residue from H1 (K412) of PvDBPII and residues from each of helices H3, H4 and H5, 223 
as well as the loops that link these helices. The contacts are predominantly mediated by hydrogen 224 
bonds between DB9 and hydrophilic residues from PvDBPII. 225 
 226 
In light of the broadly inhibitory potential of DB9, we next compared the position of the epitope with 227 
the locations of known polymorphic residues on PvDBPII. The protein is known to be polymorphic 228 
with an alignment of globally disparate sequences of PvDBPII finding over 120 polymorphic sites with 229 
nucleotide diversity varying between 0.006 and 0.0109 [38]. We retrieved 383 amino acid sequences 230 
of PvDBPII and calculated their sequence entropies. This revealed that the surface of PvDBPII 231 
contacted by DB9 is one of the most conserved regions of the domain, with low sequence variation, 232 
explaining its broadly reactive nature (Figure 6B and Figure S2). 233 
 234 
In the membrane context PvDBPII is thought to form a dimer, which can then interact with the 235 
extracellular domains of DARC. A crystal structure is available for a dimer of PvDBPII bound to a 236 
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small helix, consisting of residues 19-30 of the extracellular ectodomain of DARC [15]. We next 237 
superimposed our PvDBPII:DB9 structure onto this structure. This suggests a potential model for 238 
how DB9 might inhibit invasion by P. vivax (Figure 6C). While DB9 binds at a distance from the 239 
known region of the DARC binding site, it protrudes from subdomain 3 in the same direction as the 240 
C-terminus of the DARC19-30 peptide. This end of the DARC peptide will face the transmembrane 241 
region of DARC, located in the reticulocyte membrane. Although the arrangement of DARC31-60 is 242 
currently unknown, this model suggests that DB9 prevents the PvDBPII dimer from approaching the 243 
reticulocyte membrane in an orientation which is compatible with DARC binding, thereby preventing 244 
initiation of the invasion process. 245 
 246 
With the epitope for DB9 contained solely within subdomain 3, we next assessed the degree to 247 
which the other mAbs bind to this region. Subdomain 3 was produced by refolding material 248 
expressed in E. coli. An ELISA-based binding assay showed that 6 of the 10 mAbs bound subdomain 3 249 
(Figure S3). With the exception of DB4, the mAbs that bind subdomain 3 were those that competed 250 
for binding on PvDBPII (Figure 1C). Also interesting to note is that, with the exception of DB4, the 251 
mAbs that bind to subdomain 3 are not those that antagonise the effect of DB9. Therefore, despite 252 
the fact that antibodies that target subdomain 3 differ in their inhibitory potential, these data 253 
identify subdomain 3 of PvDBPII as a promising potential target for broadly inhibitory antibodies, 254 
and identify the epitope of one such antibody.  255 
  256 
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DISCUSSION 257 
The Duffy-binding protein is the most promising candidate for inclusion in a vaccine to prevent P. 258 
vivax due to its essential interaction with human DARC during reticulocyte invasion. While it has 259 
been shown that antibodies which bind to PvDBP are found in individuals from malaria endemic 260 
regions, and their presence associates with protection from clinical vivax malaria [23-25], no human 261 
monoclonal antibody has been reported which targets PvDBP and displays broadly inhibitory 262 
potential. We have therefore used vaccination of human volunteers with PvDBPII to induce a 263 
humoral response and have isolated a monoclonal antibody which can inhibit all tested isolates of P. 264 
vivax from invading blood cells in a functional anti-parasitic assay. This monoclonal antibody has the 265 
potential to be used directly as a prophylactic to prevent vivax malaria and its epitope provides 266 
insight to guide future vaccine development. 267 
 268 
The panel of mAbs generated in this study has been analysed through a series of complementary 269 
approaches and the differing outcomes of these assays illustrate the need for caution in attributing 270 
broadly inhibitory potential. The most accessible assay involves an analysis of purified protein 271 
binding in an ELISA-based format, with test antibodies assessed for their ability to prevent 272 
recombinant PvDBPII from binding to the N-terminal DARC ectodomain, with the assumption that 273 
direct prevention of DARC binding is the goal for a protective antibody. This assay allows for the use 274 
of PvDBPII variants to assess the breadth of inhibitory potential and identified two antibodies that 275 
broadly inhibited DARC binding (DB9 and DB2), and three with vaccine-homologous (SalI sequence) 276 
binding-inhibition activity (DB5, DB6 and DB7). 277 
  278 
With the blood-stage of P. vivax still proving impossible to sustain in long-term in vitro culture 279 
conditions, this study also made the first use of a novel, culture-compatible transgenic parasite-280 
based assay using the closely related simian malaria, P. knowlesi. Here the Duffy-binding protein, 281 
PkDBPα was replaced by PvDBP, generating novel parasite lines in which human RBC invasion 282 
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inhibition can be studied in a laboratory setting using long-term culture. This assay showed a clear 283 
hierarchy of mAb potency against the transgenic parasites in vitro, and showed similar results for 284 
parasites where the PkDBPβ and PkDBPγ genes had also been removed. Only one mAb (DB7) 285 
showed modest cross-reactive GIA against the wild-type P. knowlesi strain. Most informatively, the 286 
outcomes of this study only partially overlapped with those of the protein-based study, with some 287 
antibodies (i.e. DB1 and DB10) among those with the greatest potency to block parasite invasion and 288 
yet proving ineffective at blocking the PvDBPII-DARC interaction in a protein-protein assay.  289 
 290 
Finally, we used the most authentic in vitro assay available, by assessing the invasion of reticulocytes 291 
by ex-vivo P. vivax, taken directly from patient isolates. When studying parasite isolates which 292 
expressed the SalI PvDBPII variant (matching that used in the transgenic P. knowlesi assays), these 293 
studies give a very similar outcome to the transgenic P. knowlesi assays (Figures 3A and 4B). 294 
However, when studying isolates with heterologous PvDBPII sequences, the outcomes are different. 295 
Here, one particular antibody, DB9, outperformed all of the rest in its capacity to inhibit reticulocyte 296 
invasion by all tested strains. A comparison of data from these three assays suggests that use of 297 
protein-protein analysis will miss valuable inhibitory antibodies and highlights the applicability of a 298 
transgenic P. knowlesi-based assay as an accessible in vitro proxy for the ex-vivo analysis of P. vivax. 299 
Future studies will use a panel of such transgenic parasites, engineered to express different PvDBPII 300 
variants, to allow the assessment of broadly-inhibitory potential of future vaccine approaches. 301 
 302 
A variety of properties have been suggested as desirable for inhibitory antibodies that target PvDBP, 303 
including direct steric block of the DARC binding site or inhibition of dimerization [6, 13]. In contrast 304 
to these, DB9 binds distantly from either the DARC-binding or dimerisation interfaces, on a non-305 
polymorphic site on the distal surface of subdomain 3. Remarkably, when DB9 binds to this surface, 306 
it also prevents recombinant PvDBPII from binding to DARC that is immobilised onto an ELISA plate. 307 
A composite model, in which the structure of DB9 is docked onto the structure of a dimer of PvDBPII 308 
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bound to the 19-30 peptide from DARC shows that DB9 emerges from the same side of PvDBPII as 309 
the C-terminus of the DARC peptide. This suggests that it may sterically prevent dimeric PvDBPII 310 
from approaching a DARC coated surface, either on an ELISA plate or a reticulocyte membrane, and 311 
thereby prevent receptor engagement and invasion. 312 
 313 
These findings have significant consequences for vaccine development, identifying subdomain 3 of 314 
PvDBPII as an important region for the presentation of broadly-inhibitory epitopes for human 315 
antibodies. Not all of the antibodies identified to bind to subdomain 3 are inhibitory. However, our 316 
discovery of a set of antibodies which bind to PvDBPII and antagonise the function of the broadly 317 
inhibitory DB9 also raises the imperative for future vaccine design to avoid inducing these 318 
deleterious antibodies. It is therefore encouraging to note that 80% of the antibodies that 319 
antagonise the function of DB9 do not recognise subdomain 3. This suggests future vaccination 320 
strategies in which the surface of subdomain 3 containing the DB9 epitope is specifically presented 321 
to the immune system in the form of a vaccine immunogen. Such an approach has the potential to 322 
generate the malaria vaccines of the future. 323 
  324 
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METHODS 356 
 357 
Generation of monoclonal antibodies 358 
Plasmablast isolation and sorting: Volunteers from a Phase Ia clinical trial were bled seven days 359 
after the second immunisation using MVA (modified vaccinia virus Ankara) encoding PvDBPII [19]. 360 
Blood was collected from volunteers in heparinised tubes and centrifuged in Leucosep tubes 361 
(Greiner Bio-One) to separate the peripheral blood mononuclear cells (PBMC). The PBMC were 362 
enriched for B cells using a human pan-B cell enrichment kit (Easysep) and re-suspended in DMEM 363 
before staining with a CD19+, CD10–, CD21–, CD27+, CD20–, CD38+, IgG+ fluorophore-conjugated 364 
antibody panel. Plasmablasts were single-cell sorted using a MoFlo cell sorter (DakoCytomation) into 365 
96-well PCR plates containing 10 µL 10 mM Tris HCl buffer containing 40 U/mL of RNase inhibitor 366 
(Promega). The study received ethical approval from the Oxfordshire Research Ethics Committee A 367 
in the UK (REC reference 13/SC/0001). The volunteers signed consent forms and consent was 368 
verified before each vaccination. 369 
 370 
Antibody variable gene amplification: In wells of a 96-well plate, each containing a single antibody-371 
secreting cell (ASC), a two-step RT-PCR was carried out with a first reverse transcription (RT) step 372 
using a Sensiscript RT kit (Qiagen) and degenerate primers 1-17 (modified from [39], see 373 
Supplemental Experimental Procedures Table 1). Next, a PCR was performed on 1 µL of the RT 374 
reaction product using the same set of primers used before (1-17) which cover the diversity of all Vγ, 375 
Vκ and Vλ sequences using Phusion HF master mix (New England Biolabs). Following this, a nested 376 
PCR was performed with primers 18-51, also using Phusion HF master mix, (Supplemental 377 
Experimental Procedures Table 1) on 1 µL of the previous product diluted 1:100 to amplify inserts 378 
which contain plasmid-homologous extensions designed for circular polymerase extension cloning 379 
[40]. 380 
 381 
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Cloning: The AbVec-hIgG1/AbVec-hIgKappa/AbVec-hIgLambda expression plasmids were a kind gift 382 
from Patrick C. Wilson (University of Chicago) [41]. These plasmids were 5’ digested using BshTI and 383 
at the 3’ using SalI (AbVec-hIgG1), XhoI (AbVec-hIgLambda) and Pfl23II (AbVec-hIgKappa) to yield 384 
linear products. CPEC assembly was performed by mixing 100 ng of a 1:1 molar ratio of 385 
insert:plasmid in 20 µL containing 1x Phusion HF polymerase master mix and assembled using an 8-386 
cycle CPEC protocol (8 cycles: 98 ˚C 10 s, slow ramp anneal 70 ˚C  55 ˚C at 0.1 ˚C/s, 72 ˚C 35 s). Full 387 
nicked plasmids were then transformed into Zymo 5α Mix & go competent Escherichia coli (Zymo 388 
Research) according to manufacturer’s instructions, streaked on LB agar petri dishes containing 100 389 
µg/mL carbenicillin and grown at 37°C overnight in a static incubator. Colonies were screened by 390 
PCR for correctly sized inserts. 391 
 392 
Screening: Exponential growth-phase adherent HEK293 cells were re-suspended in DMEM (Sigma-393 
Aldrich) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 1 mM sodium pyruvate, 0.1 394 
mg/mL streptomycin and 10 % ultra-low IgG foetal bovine serum (FBS) (Thermo Fischer Scientific) 395 
and seeded at 4 x 104 cells/well in 100 µL 24 h prior to transfection in Costar 96-well cell culture 396 
plates (Corning). On the day of transfection, for each well, 50 µL of 60 µg/mL linear 25 kDa PEI (Alfa 397 
Aesar) was mixed with 200 ng of cognate heavy- and light-chain coding plasmid in a volume of 50 µL 398 
and shaken at 20°C for 30 min. The DNA-PEI complexes were added to the HEK293 cells. The 399 
following day, an additional 50 µL of supplemented DMEM (as described above) was added to each 400 
well. Supernatants were screened for PvDBPII (produced in S2 cells as described below) binding by 401 
indirect ELISA. 402 
 403 
Recombinant protein constructs, expression and purification 404 
The production of the recombinant PvDBPII used in the IgG screening assay described above, the 405 
DARC-binding inhibition assays (Figure 2) and the SPR assays (Figure 1A-D), from Drosophila S2 cells 406 
has been previously described [19]. In brief; the sequence used was identical to the vaccine 407 
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sequence; D194–T521 of PvDBPII (SalI), with T257A, S353A and T422A substitutions to remove sites 408 
of possible N-linked glycosylation, followed by a shortened Pk/V5 epitope tag (IPNPLLGLD) and a C-409 
tag (EPEA) [42] for detection and purification, respectively. Purification was performed on an AKTA 410 
Pure 25 system (GE Healthcare, UK), consisting of an affinity step with CaptureSelect™ C-tag column 411 
(Thermo Fisher Scientific, UK) and a polishing size exclusion chromatography (SEC) using Superdex 412 
200 16/60 PG (GE Healthcare, UK) in 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 (TBS). Purified protein 413 
was quantified by Nanodrop (Thermo Fisher Scientific, UK) and stored at -80°C until further use. A 414 
gene encoding the PvDBPII HMP013 allele [19] (aa 194-521) was codon optimised for human 415 
expression and synthesised (Genewiz, USA). This sequence, with a 5’ KpnI site and 3’ XbaI site, was 416 
cloned into a mammalian expression plasmid in frame with an N-terminal mouse IgK light chain 417 
leader sequence and a C-terminal C-tag prior to the stop codon. Suspension EXPI293F cells (Thermo 418 
Fisher Scientific, UK) were transiently transfected and culture supernatants were harvested after 4 419 
days. Purification was performed on an AKTA Pure 25 system (GE Healthcare, UK), consisting of an 420 
affinity step with CaptureSelect™ C-tag column (Thermo Fisher Scientific, UK) and a polishing SEC 421 
step using Superdex 200 Increase 10/300 GL (GE Healthcare, UK) in 20 mM Tris-HCl, 150 mM NaCl, 422 
0.1% Tween 20, pH 7.4 (TBS). Purified protein was quantified by Nanodrop (Thermo Fisher Scientific, 423 
UK) and stored at -80°C until further use. 424 
The PvAH, PvO and PvP alleles  of PvDBPII [43] used in the DARC binding-inhibition assays (Figure 2) 425 
were a kind gift from Chetan Chitnis. 426 
Monobiotinylated PvDBPII supernatant was produced for use in the BLI experiments (Figures 1E-G) 427 
by transient transfection of suspension EXPI293F cells, using a plasmid encoding PvDBPII (SalI) with 428 
C-terminal rat CD4 domains 3 and 4 followed by a biotin acceptor peptide obtained from Addgene 429 
(plasmid #68529) and courtesy of Dr Julian Rayner (Wellcome Trust Sanger Institute, Hinxton, UK) 430 
[44]. This PvDBPII plasmid was co-transfected with another plasmid encoding E. coli biotin ligase 431 
(BirA). Supernatant was harvested after 4 days, clarified, dialysed against PBS using snakeskin and 432 
concentrated ~10-fold using spin columns. 433 
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The production of the PvDBPII and PvDBPII subdomain 3 proteins used in the crystal complex (Figure 434 
6) and the subdomain 3 binding ELISA (Figure S3) is described in ‘Structural Methods’ below. 435 
The production of recombinant N-terminal DARC, used in the DARC-binding inhibition assays, has 436 
been previously described [19]. In brief; a gene encoding the first 60 amino acids of DARC Fyb allele 437 
(GenBank Accession #ABA10433.1) followed by a thrombin cleavage site (LVPRGS) and an AviTag 438 
(GLNDIFEAQKIEWHE) was codon-optimised for E. coli expression and synthesised (GeneArt, Life 439 
Technologies). Cysteines 4, 51 and 54 of DARC were mutated to alanine. This sequence with 5’ KpnI 440 
site and 3’ BamHI site was cloned into a mammalian expression plasmid in-frame with an N-terminal 441 
human tissue plasminogen activator (tPA) leader sequence [20] and a C-terminal hexa-histidine 442 
(His6) tag prior to the stop codon. Suspension HEK293E cells grown in EXPI293 expression medium 443 
(Thermo Fisher Scientific, UK) were transiently transfected with plasmid and allowed to grow for 444 
three days before the supernatant was harvested, purified using a HisTrap Excel column (GE 445 
Healthcare, UK) and buffer exchanged into PBS. Purified protein was quantified by Nanodrop 446 
(Thermo Fisher Scientific, UK) and stored at -80°C until further use. 447 
Recombinant monoclonal antibodies were transiently expressed in HEK293F cells using the 448 
Expi293™ Expression System (Thermo Fischer Scientific) according to the manufacturer’s 449 
recommendations. Cognate heavy and light chain-coding plasmids were co-transfected at a 1:1 ratio. 450 
Supernatants were harvested by centrifuging the culture at 2500 xg for 15 min and filtering the 451 
supernatant with a 0.22 µm vacuum filter. All mAbs were purified using a 5 mL Protein G HP column 452 
(GE Healthcare) on an ÄKTA start FPLC system or an ÄKTA Pure FPLC system (both GE Healthcare). 453 
Equilibration and wash steps were performed with Dulbecco’s PBS and mAbs were eluted in 0.1 M 454 
glycine pH 2.7. The eluates were pH equilibrated to 7.4 using 1.0 M Tris HCl pH 9.0 and immediately 455 
buffer-exchanged into Dulbecco’s PBS and concentrated using an Amicon® ultra centrifugal 456 
concentrator (Millipore) with a molecular weight cut-off of 30 kDa.  457 
 458 
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Bio-Layer Interferometry (BLI) 459 
BLI was carried out on an OctetRED384 (Pall FortéBio) using streptavidin-coated biosensors (Pall 460 
FortéBio) to immobilise PvDBPII enzymatically monobiotinylated on a C-terminal AviTag™. Assays 461 
were carried out in 96-well format in black plates (Greiner). For epitope binning studies (Figure 1E-462 
G), a six-step sequential assay was performed: Baseline (PBS, 30 s); Protein immobilisation (neat 463 
supernatant, 120 s); Wash (PBS, 60 s); first mAb (mAb1) binding (300 nM mAb1, 120 s); Wash (PBS, 464 
60 s); second mAb (mAb2) binding (150 nM mAb2, 120 s). “Relative binding” in Figure 1E shows the 465 
ratio (SignalmAb2 with mAb1 bound)/(SignalmAb2 with no mAb1) where “SignalmAb2” was normalised for 466 
the amount of PvDBPII bound to the biosensor, such that “SignalmAb2” = the raw signal in “mAb2 467 
binding” divided by the raw signal in the “Protein immobilisation” phase. The resulting “binding 468 
profile” for any given mAb corresponds to the column of “relative binding values” under that mAb in 469 
the “relative binding” table. To establish the epitope bins, binding profiles between each mAb pair 470 
were correlated using a Pearson product-moment correlation coefficient, the values of which are 471 
shown in the “binding profile correlation” matrix in Figure 1F. mAb pairs whose binding profile 472 
correlation was > 0.7 were grouped into the same epitope bin (Figure 1G). 473 
 474 
Measurement of binding by ELISA 475 
Qualitative mAb binding ELISAs such as those used in Figure S3 were carried out by coating PvDBPII 476 
or PvDBPII subdomain 3, produced as described in ‘Structural Methods’ above, on Maxisorp flat-477 
bottom 96-well ELISA plates (Nunc) at 2 µg/mL in 50 µL at 4 °C overnight. Plates were then washed 478 
twice with PBS and 0.05% Tween 20 (PBS/T) and blocked with 200 µL of Blocker™ Casein (Thermo 479 
Fischer Scientific) for 1 h. Next, wells were incubated with 1000 ng/mL of mAb for approximately 45 480 
min at 20 °C then washed 4 times with PBS/T before the addition of 50 µL of goat anti-human 481 
gamma-chain alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich) for 45 min at 20 482 
°C. Wells were then washed 6 times with PBS/T and developed with 100 µL of p-nitrophenyl 483 
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phosphate substrate at 1 mg/mL (Sigma-Aldrich) and optical density read at 405 nm (OD405) using a 484 
Model 550 Microplate Reader (Bio-Rad, UK).  485 
 486 
Affinity determination by SPR 487 
Data were collected on a Biacore X100 (GE Healthcare). Experiments were performed at 25 °C in 488 
Dulbecco’s PBS + 0.005 % Polysorbate-20 (GE Healthcare). In Figure 1 and Table S2 a sensor chip 489 
protein A (GE Healthcare) was used to capture 50-100 RU of purified mAb diluted in SPR running 490 
buffer at a flow rate of 5 µL/min on flow cell 2. Next, an appropriate range (typically 20 nM-0.625 491 
nM) of six 2-fold dilutions, with one replicate, of PvDBPII (expressed in S2 cells as described above) 492 
was injected for 90 s at 60 µL/min and dissociation was measured for 1600 s (7200 s when 493 
necessary). Specific binding of the PvDBPII protein to mAb was obtained by reference-subtracting 494 
the response of a blank surface from that of the mAb-coated surface. The sensor surface was 495 
regenerated with a 60 s pulse of 10 mM glycine-HCl pH 1.5 (GE Healthcare). Sensorgrams were fitted 496 
to a global Langmuir 1:1 interaction model, allowing determination of the kinetic association and 497 
dissociation rate constants using Biacore X100 evaluation software. 498 
 499 
PvDBPII-DARC binding inhibition assays 500 
This assay methodology has been previously reported [19, 29]. In brief; recombinant N-terminal 501 
DARC protein was coated onto Nunc-Immuno Maxisorp plates at 1 μg/mL. mAb samples were 502 
diluted down in a 2-fold series (starting at 100 µg/mL) and pre-incubated with PvDBPII protein for 30 503 
min at room temperature (RT). The pre-incubated PvDBPII protein plus mAb mixture was then added 504 
to the DARC-coated plates (in duplicate wells). The plates were incubated for 1 h at 37 °C, washed 505 
and then incubated with anti-PvDBPII polyclonal rabbit serum [20]. After a further wash step, the 506 
plates were incubated with a 1:1000 dilution of anti-rabbit IgG alkaline phosphatase (Sigma Aldrich, 507 
UK) and then developed with 1 mg/mL p-nitrophenyl phosphate in diethanolamine buffer (Pierce, 508 
UK). OD405 was read using a Model 550 Microplate Reader (Bio-Rad, UK) when control wells 509 
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containing PvDBPII protein and buffer only reached a value of 1.0. In one column of each 96 well 510 
plate, wells contained only mAb (100 µg /ml) and buffer (no PvDBPII protein) and these ‘background’ 511 
OD405 values were subtracted from all test values. To calculate % binding-inhibition for each mAb 512 
sample the formula below was used: 513 
1 – (OD405 value of mAb sample / OD405 value of negative control sample) x 100  514 
Five allelic variants of recombinant PvDBPII were used in the assay; Sal1, which was made in S2 cells 515 
as described above; PvAH, PvO and PvP alleles [43], which were a kind gift from Chetan Chitnis; and 516 
PvHMP013, which was sequenced from a vivax-infected patient in Australia [45]. The expression of 517 
recombinant PvDBPII HMP013 protein has been previously described [19] and is summarised above. 518 
An anti-Ebolavirus glycoprotein-reactive human IgG1 mAb ‘EBL040’ (Rijal P et al., submitted) was 519 
used as a negative isotype control for mAb samples. Polyclonal human anti-PvDBPII serum from the 520 
clinical trial [19] was used as the positive control. 521 
 522 
Genetic modification of P. knowlesi parasites 523 
The genetic modification of P. knowlesi A1H1 strain [30] is described in detail elsewhere (Mohring F 524 
et al., manuscript under ). Briefly, parasites were modified using a two-plasmid CRISPR-Cas9 525 
system, comprised of a plasmid (pCas/sg) providing Cas9, sgRNA, and a hDHFR-yFCU (for positive 526 
and negative selection) to create a locus specific double strand break and a separate “donor” DNA 527 
plasmid  (pDonor) to act as the repair template. To create the PkDBPαOR or PvDBPOR lines the 528 
PkDBPα locus (sgRNA: GCTGATCCAGGTTCTCAATC)  was targeted using a pDonor plasmid 529 
containing full length recodonised PkDBPα or PvDBP (SalI) genes respectively, both flanked by 500 530 
bp homology regions targetting the 5’UTR and 3’UTR of PkDBPα. To create the PkDBPαOR/Δβγ and 531 
PvDBPOR/Δβγ lines this process was repeated in an A1-H.1 line which had a natural deletion of DBPβ  532 
(truncation of chromosome 14) and then a subsequent round of gene editing used to delete the 533 
DBPγ locus (sgRNA: CATGCAACAATTTACACCCC) using a pDonor plasmid containing a spacer 534 
sequence flanked by 500 bp homology regions targetting the 5’UTR and 3’UTR of PkDBPγ. 535 
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 536 
Assays of growth inhibitory activity (GIA) with P. knowlesi lines 537 
In vitro parasite culture and synchronisation. Human RBC-adapted parasites were maintained in 538 
culture as previously described [30]. Briefly, parasites were grown at 2 % haematocrit in O+ human 539 
RBC, which were prepared twice monthly. Culture medium contained 10 % heat-inactivated pooled 540 
human serum mixed with RPMI 1640 supplemented with 25 mM HEPES, 35 μM hypoxanthine, 2 mM 541 
L-glutamine and 20 μg/mL gentamycin. Parasite cultures were synchronised at trophozoite/schizont 542 
stage by magnetic separation (MACS LS columns, Miltenyi Biotech). 543 
In vitro assay of GIA. Methodology was adapted from the protocol of the International GIA 544 
Reference Centre at NIH, USA [46]. Synchronised trophozoites were adjusted to 1.5 % parasitaemia, 545 
and 20 μL aliquots were pipetted into 96-well flat/half area tissue culture cluster plates (Appleton 546 
Woods). 20 μL test antibody or controls were added in duplicate or triplicate test wells over a 547 
concentration range (usually; 1, 0.5, 0.25, 0.125, 0.0625, 0.0312, 0.015 and 0.0075 mg/mL) and 548 
incubated for one erythrocytic parasite cycle (26-30 h). Parasitaemia was measured using the lactate 549 
dehydrogenase (pLDH) activity assay following standard protocols [47]. Percentage GIA was 550 
calculated as below; 551 
% GIA = 100 – 100 (Sample A650 – Uninfected RBC A650)/(Infected ControlA650 − Uninfected RBC A650) 552 
An anti-DARC VHH camelid nanobody [48], a kind gift from Dr Olivier Bertrand (INSERM, France) was 553 
included in the test plate as a positive control in every assay (at a final concentration of 6, 3 or 1.5 554 
μg/mL) and an anti-Ebolavirus glycoprotein-reactive human IgG1 mAb as a negative isotype control 555 
for mAb samples. The assays were performed using five different lines of P. knowlesi parasites; the 556 
non-transgenic strain (PkA1H1); two transgenic lines containing the PvDBP gene (PvDBPOR and 557 
PvDBPOR/Δβγ) and two transgenic control lines (PkDBPαOR and PkDBPαOR/Δβγ) (Mohring F et al., 558 
submitted). In the mAb synergy assays (Figure 5) ‘Bliss additivity’ between two mAbs (mAb A and 559 
mAb B) was calculated using the formula below.  560 
𝐆𝐆𝐆𝐆𝐆𝐆 [𝐆𝐆 + 𝐁𝐁] 𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁 = �𝟏𝟏 − �𝟏𝟏 − 𝐆𝐆𝐆𝐆𝐆𝐆 𝐆𝐆
𝟏𝟏𝟏𝟏𝟏𝟏
� ∗ �𝟏𝟏 −  𝐆𝐆𝐆𝐆𝐆𝐆 𝐁𝐁
𝟏𝟏𝟏𝟏𝟏𝟏
�� ∗ 𝟏𝟏𝟏𝟏𝟏𝟏  561 
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 562 
Ex-vivo P. vivax invasion assays 563 
The assay methodology has been previously described [49, 50]. The major steps are summarised 564 
below. 565 
Purification of reticulocytes from umbilical cord blood: 20 mL aliquots of umbilical cord blood were 566 
collected from consenting volunteers (OXTREC 027-025 (Center for Clinical Vaccinology and Tropical 567 
Medicine, University of Oxford, Oxford, United Kingdom) and MUTM 2008-215 from the Ethics 568 
Committee of the Faculty of Tropical Medicine (Mahidol University, Bangkok, Thailand)) in lithium 569 
heparin tubes and the white blood cells and platelets depleted using Non-woven filters™ (Antoshin). 570 
The RBC were then layered onto 70 % isotonic Percoll, centrifuged and the resulting band of 571 
enriched reticulocytes was incubated with anti-CD71 MicroBeads (Miltenyi) before being passed 572 
through a large selection (LS) column (Miltenyi) to obtain a CD71-depleted (negative) fraction and a 573 
CD71-rich fraction (positive). The purity levels of these CD71+ fractions were assessed with 574 
microscopy using new methylene blue staining (Sigma-Aldrich).  575 
Purification of schizonts from ex-vivo P. vivax-infected blood samples: 5 mL samples of whole 576 
blood were collected from consenting patients (OXTREC 027-025 (Center for Clinical 577 
Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom) 578 
and MUTM 2008-215 from the Ethics Committee of the Faculty of Tropical Medicine 579 
(Mahidol University, Bangkok, Thailand)) diagnosed with P. vivax malaria and rapidly transported at 580 
RT back to the laboratory. Samples were not collected from patients who had taken antimalarial or 581 
antimicrobial drugs within the previous month, or whose parasitaemia was < 0.1 % on smear 582 
microscopy. The samples were leukodepleted using Non-woven filters™ (Antoshin), and the 583 
parasites were cultured to schizont stage. The culture was then treated with trypsin, overlaid on a 45 584 
% Percoll (isotonic) cushion and centrifuged to isolate a fine band of concentrated schizonts for use 585 
in the assay. 586 
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Invasion assay: The concentrated schizont preparation was mixed with the enriched reticulocyte 587 
fraction at a ratio of 1:6, giving a starting schizont parasitaemia of ~14 %. The mixture was diluted to 588 
1.3 % haematocrit in 300 μL of complete McCoy 5A medium and cultured in 96-well cell culture 589 
plates in an atmosphere of 5 % O2 at 37.5 °C. Test antibodies and controls were buffer exchanged 590 
into Pv culture medium (McCoy 5A medium (Gibco) supplemented with 2.4 g/L D-glucose, 40 mg/mL 591 
gentamycin sulfate, and 20% heat-inactivated human AB serum) and added to the final invasion 592 
assay mixture at the desired concentration. In the case of the anti-PvDBPII mAbs this was 1 mg/mL. 593 
The anti-DARC nanobody, at 25 μg/mL, and the recombinant IgG1 anti-Ebolavirus mAb, at 1mg/mL, 594 
were added to all assays as positive and negative controls respectively. Maturation was obtained 595 
after incubation for an average of 24 h. At the end of the incubation period, thin smears (each made 596 
with 1 μL packed cells) were made, and stained with Giemsa (Sigma-Aldrich). The number of ring 597 
stages and trophozoites per 4000 erythrocytes was determined by examining the Giemsa thin film 598 
smears by light microscopy. For isolates #1-3, the invasion assays were performed in Singapore using 599 
cryopreserved Thai P.vivax isolates and reticulocyte invasion inhibition was quantified by flow 600 
cytometry as previously described [49]. 601 
 602 
Sequencing of the PvDBPII gene from Thai isolates: Genomic DNA was extracted either from an 603 
aliquot (200 μL) of the initial blood sample or from a dried blood spot, using the DNeasy Blood and 604 
Tissue kit (QIAGEN). PCR amplification was performed on 1 μL purified genomic DNA in a total 605 
volume of 50 μL, containing 1x PCR buffer, 2.5 mM MgCl2, 0.2 mM of each dNTP, 2 μM each primer 606 
(forward 5’ – gtg act ggg cat gag gga aat tct cg and reverse 5’ – gcg tag aat ctc ctg gaa cct tct cc) and 607 
1.25U of AmpliTaq Gold DNA polymerase (Applied Biosystems). The cycling conditions were: 95 °C 608 
for 5 min followed by 30 cycles at 94 °C for 1 min, 63 °C for 2 min, and 72 °C for 2 min. The product 609 
was purified using the QIAquick PCR purification kit (QIAGEN) and then sequenced (GATC biotech). 610 
 611 
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Structural Methods 612 
Protein Cloning, Expression and Purification 613 
PvDBPII coding region (residues 211-507; SalI sequence) was cloned into pET15b vector. This vector 614 
allowed expression of the protein with an N-terminal His6 tag and a TEV cleavage site, in E. coli 615 
(BL21-DE3 strain). The transformed bacteria were induced with 1 mM IPTG at an optical density of 616 
0.8 at 600 nm. PvDBPII was expressed exclusively in inclusion bodies and was prepared as previously 617 
described [15]. In short, the inclusion bodies were solubilised in 6 M guanidine hydrochloride, 20 618 
mM Tris pH8, 300 mM NaCl, and refolded by flash-dilution into 400 mM L-arginine, 50 mM Tris pH8, 619 
10 mM EDTA, 0.1 mM PMSF, 3 mM reduced glutathione, and 0.3 mM oxidised glutathione. Refolded 620 
proteins were buffer exchanged into 20 mM Tris pH8, 150 mM NaCl, 20 mM imidazole and then 621 
affinity purified on NiNTA resin. The His-tag was removed by TEV protease cleavage and the tagless 622 
PvDBPII was separated from the His-tag on NiNTA resin and purified by SEC (S75 16/60, GE 623 
Healthcare) into 20 mM Hepes pH7.5, 150 mM NaCl.  624 
 625 
Subdomain3 (Sd3) (residues 211-508) was subcloned from the PvDBPII construct in the pET15b 626 
vector. Sd3 also expressed in E. coli BL21 (DE3) cells in the insoluble fraction and was solubilised in 6 627 
M guanidine hydrochloride, 20 mM Tris (pH8), 150 mM NaCl, 20 mM imidazole. Sd3 was then 628 
refolded by binding to a NiNTA column and gradually decreasing the concentration of guanidine 629 
hydrochloride, until the protein was in 20 mM Tris (pH8), 150 mM NaCl, 20 mM imidazole. The 630 
refolded Sd3 protein was then eluted and further purified using SEC (S75 16/60 GE Healthcare) into 631 
20 mM Hepes pH7.5, 150 mM NaCl. 632 
 633 
Fab Generation and Purification 634 
Fab fragments for DB9 were generated from IgG by incubating with immobilised papain 635 
(ThermoFisher Scientific) for 16 h at 37 °C. The Fab was separated from the un-cleaved DB9 and Fc 636 
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regions using protein A resin (ThermoFisher Scientific). The Fab fragments were then purified by SEC 637 
into 20 mM Hepes pH7.5, 150 mM NaCl. 638 
 639 
Protein Cystallisation and Data Collection 640 
PvDBPII and DB9Fab were mixed in a 1.2:1 molar ratio and incubated at RT for 1 h. The complex was 641 
purified by SEC (S75, GE Healthcare) in 20 mM Hepes pH7.5, 150 mM NaCl. Broad crystallisation 642 
trials were set up by sitting-drop vapour diffusion in SwisSci 96-well plates by mixing 100 nl protein 643 
with 100 nl reservoir solution. Crystals grew in the reservoir solution of 45 % v/v polypropylene 644 
glycol 400, 10% v/v ethanol and were then cryo-cooled in liquid nitrogen. Data were collected on 645 
beamline I03 at Diamond Light Source and were indexed and scaled using Scaler [51] to a resolution 646 
of 3.04 Å. 647 
 648 
Structure Solution 649 
The PvDBPII:DB9Fab structure was solved by molecular replacement in Phaser [52] using the known 650 
structures of PvDBPII (PDB 4NUV) and a human mAb Fab fragment (PDB: 3DIF), separated into two 651 
files containing the variable and constant regions, as search models. This identified one copy of the 652 
PvDBPII:DB9 complex in the asymmetric unit. Refinement and rebuilding was completed using 653 
Buster [53] and Coot [54], respectively.  654 
 655 
Statistical Analyses 656 
Data were analysed using GraphPad Prism version 6.07 for Windows (GraphPad Software Inc.). In 657 
Figures 3A, a four-parameter sigmoidal dose-response curve was fitted to the relationship 658 
between log10 (antibody concentration) and percentage GIA for each dataset and used to 659 
interpolate EC30 values. In Figure 3B, the nonparametric Spearman’s rank correlation coefficient 660 
(ρ) was used to assess a correlation between the variables Kon/Koff/KD and GIA EC30. In all 661 
statistical tests the P values reported are two-tailed with P < 0.05 considered significant.  662 
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 800 
Figure 1: Binding kinetics and epitope bins for the human anti-PvDBPII mAb panel. 801 
Kinetic rate constants of binding for ten human mAbs (DB1-DB10) to PvDBPII as determined by SPR. 802 
(A) Association rate constant (kon); (B) Dissociation rate constant (koff); (C) Association constant 803 
(1/KD); and (D) Iso-affinity plot of kon against the koff. (E) A “relative binding” matrix showing the 804 
fraction of the second mAb bound to PvDBPII in the presence of bound first mAb. Assays were 805 
carried out in both orientations. Boxes are color-coded such that values ≥ 0.75 are in blue, 0.75 > X > 806 
0.05 are in pink and ≤ 0.05 are in red. Negative values were normalised to 0 and values >1 were 807 
normalised to 1. (F) A “binding profile correlation” matrix showing the Pearson product-moment 808 
correlation values of each mAb pair. The correlation threshold was set at 0.7; values equal to or 809 
above this are coloured in red as the threshold chosen to represent competition. (G) Epitope bins 810 
determined from E and F. 811 
 812 
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 813 
Figure 2: Inhibition of the binding of recombinant PvDBPII to DARC ectodomain.   814 
(A) Assessment of the % binding of five naturally occurring variants of PvDBPII to the DARC 815 
ectodomain in vitro in the presence of 100 µg/mL concentration of each mAb (DB1-DB10). Individual 816 
titration curves are shown in Figure S1. “αDBP” is polyclonal human anti-PvDBPII serum at 1:5 817 
dilution while ‘ebola’ is an anti-Ebolavirus recombinant human IgG1 mAb included as a negative 818 
control. Data points represent the mean and SD of triplicate test wells. (B) Sequence polymorphisms 819 
of PvDBPII variants used in the assay. Numbering is according to the SalI reference sequence. Amino 820 
acid polymorphisms are indicated for the PvDBPII variants (P, O, AH and HMP013). Amino acids that 821 
are the same as the reference sequence are indicated by a full stop, while a hyphen indicates an 822 
insertion/deletion and * indicates a leucine insertion between V429 and P430 in HMP013.  823 
 824 
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 825 
Figure 3:  Growth inhibition of transgenic P. knowlesi (Pk) lines expressing PvDBP by human mAbs.  826 
(A) Assays of GIA by the ten anti-PvDBPII human mAbs against five different Pk lines: ‘Wild type’ Pk 827 
A1H1; PkDBPOR; PkDBPOR/Δβγ; PvDBPOR and PvDBPOR/Δβγ. Inhibition was tested in a two-fold dilution 828 
series starting at 1 mg/mL. Data points represent the mean and SD of triplicate test wells. The EC50 829 
values (interpolated by non-linear regression) are shown in ascending rank order for the seven mAbs 830 
which reached >50 % GIA against PvDBPOR/Δβγ at the maximum concentration (1 mg/mL). (B) kon 831 
(on-rate), koff (off-rate) and KD (dissociation constant), plotted against GIA EC30 for PvDBPOR/Δβγ. EC30 832 
values were used to include weaker-neutralising mAbs and were interpolated from non-linear 833 
regression curves. Kinetic data are as Figure 1 and Table S2. Spearman’s rank correlation coefficient 834 
(ρ) and P value are shown. 835 
  836 
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 837 
Figure 4: Inhibition of invasion of reticulocytes by Thai P. vivax clinical isolates.  838 
(A) Plasmodium vivax (Pv) ex-vivo invasion assays were performed with thirteen separate isolates of 839 
infected blood from local patients. Each data point represents the % inhibition of each antibody 840 
against one of the thirteen isolates. All antibodies were tested at a final concentration of 1 mg/mL, 841 
except the positive control anti-DARC VHH (αDARC) which was assayed at 25 μg/mL. The red bars 842 
represent the median % inhibition for each antibody. A recombinant human IgG1 anti-Ebolavirus 843 
mAb (ebola) was used as a negative control at 1mg/mL. (B) The most potently inhibitory mAbs 844 
against isolate #4 (left hand bar of each pair) and isolate #7 (right hand bar of each pair), the two 845 
isolates with SalI vaccine-homologous PvDBPII sequences (Figure 4C) to demonstrate correlation 846 
with the transgenic Pk assays of GIA (Figure 3A). (C) Amino acid polymorphisms found within the 847 
PvDBPII gene segment of the eight Thai Pv isolates for which we obtained sequence information. The 848 
vaccine homologous Salvador I (SalI) reference sequence is shown in the bottom row. Amino acids 849 
that are the same as the reference sequence are indicated by a period, a hyphen indicates an 850 
insertion/deletion and * represents a leucine insertion between V429 and P430 in the SalI reference 851 
sequence. (D) Summary matrix showing the percentage inhibition of invasion by each mAb for each 852 
of the sequenced strains. Red represents >65 % inhibition, green represents >30 – 65 % inhibition, 853 
and blue represents <30 % inhibition. The positive control was the camelid anti-DARC nanobody 854 
(VHH) at 25 μg/mL (αDARC) and the negative control was a recombinant human IgG1 anti-Ebolavirus 855 
mAb (ebola) at a concentration of 1 mg/mL.  856 
  857 
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 858 
 859 
Figure 5: Assessment of synergy, additivity and antagonism by anti-PvDBPII human mAb 860 
combinations. 861 
Assays of GIA were performed to assess the effect of other mAb specificities on the inhibitory 862 
activity of DB9 against the PvDBPOR transgenic P. knowlesi line. DB9 is present and held at a fixed 863 
concentration of 25 μg/mL, while the other mAbs are in a two-fold dilution series starting at 100 864 
μg/mL. The black line shows the % inhibition of each mAb in the absence of DB9. The red line shows 865 
the predicted additive inhibition (‘Bliss additivity’ as calculated in the equation in Methods) of the 866 
indicated mAb plus DB9 at 25 μg/mL. The blue line shows the actual observed % inhibition of the 867 
two combined mAbs. The dotted black line gives the % inhibition of DB9 alone at 25 μg/mL. Data 868 
points and error bars represent the mean and standard deviation of triplicate wells. 869 
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 870 
Figure 6: The structural basis for inhibition of PvDBPII by antibody DB9. 871 
(A) The structure of PvDBPII (pink) bound to the Fab fragment of DB9 (blue). PvDBPII is shown in two 872 
shades of pink, with subdomains 1 and 2 light pink and subdomain 3 dark pink. DB9 is in two shades 873 
with the light chain in light blue and the heavy chain in dark blue. (B) PvDBPII is shown in surface 874 
representation in grey, with residues known to be polymorphic highlighted according to their 875 
sequence entropy (yellow = 0.15-0.3, orange = 0.3-0.45 and red > 0.45). DB9 is in blue, and binds to a 876 
conserved region of PvDBPII. (C) The structure of PvDBPII:DB9 complex superimposed on the 877 
structure of the PvDBPII dimer structure bound to a peptide from the DARC ectodomain, indicating 878 
that DB9 may prevent the binding of PvDBP to DARC in the context of the reticulocyte membrane. 879 
 880 
 881 
 882 
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 883 
 884 
Figure S1: Anti-PvDBPII mAb inhibition of the binding of recombinant PvDBPII variants to the 885 
recombinant N-terminal 60 amino acid DARC ectodomain. 886 
The binding of five naturally occurring variants of PvDBPII to the DARC ectodomain in the presence 887 
of increasing concentrations of each of DB1-DB10 is shown. The variants are SalI (red), AH (green), O 888 
(brown), P (blue) and HMP013 (black). “poly” is polyclonal human anti-PvDBPII serum from the 889 
VAC051 clinical trial [19], while “ebola” is an anti-Ebolavirus recombinant human IgG1 mAb included 890 
as a negative control. Data points represent the mean and SD of triplicate test wells.  891 
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 892 
Figure S2: Sequence logo representing sequence conservation across PvDBPII. 893 
Sequence logo derived from 383 sequences of PvDBPII from P. vivax isolates. Underneath the logo is 894 
the residue number from the SalI PvDBPII variant. Cylinders represent the location of helices while 895 
lines represent loops. Above the sequence, blue kites indicate residues which directly contact DB9. 896 
Yellow, orange and red circles represent residues with sequence entropies of 0.15-0.3, 0.3-0.45 and 897 
>0.45 respectively. 898 
 899 
 900 
 901 
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 902 
Figure S3: Analysis of the binding of monoclonal antibodies to PvDBPII subdomain 3. 903 
An ELISA of the ten anti-PvDBPII mAbs (at 10 µg/mL) binding to recombinant PvDBPII (left) and 904 
subdomain 3 (right). The column heights and error bars represent the mean and SD of triplicate 905 
wells. Human polyclonal anti-PvDBPII serum (αDBP) from the VAC051 clinical trial [19] at 1:100 906 
dilution and a human anti-Ebolavirus IgG1 mAb (ebola) at 10 µg/mL were used as positive and 907 
negative controls, respectively.  908 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
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 921 
 922 
 923 
 924 
 925 
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Table S1 Genetic lineage of heavy chain variable regions from PvDBPII-specific mAbs. The 934 
percentage of nucleotide substitutions relative to germline is shown 935 
 936 
mAb Allele usage Germline change 
DB1 IGHV5-51*03  IGHD3-22*01  IGHJ3*02 1.7% (5/294) 
DB2 IGHV4-59*08  IGHD6-13*01  IGHJ3*02 1.4% (4/293) 
DB3 
IGHV4-31*03  IGHD2-2*01,IGHD2-2*02,IGHD2-2*03  
IGHJ4*02 
6.4% (19/297) 
DB4 IGHV1-69*06  IGHD6-6*01  IGHJ4*02 2.7% (8/295) 
DB5 
IGHV1-46*03  IGHD1-26*01,IGHD4-11*01,IGHD4-4*01  
IGHJ6*02 
0.7% (2/296) 
DB6 
IGHV1-2*02  IGHD3-3*02,IGHD5-12*01,IGHD6-13*01  
IGHJ6*02 
2.4% (7/294) 
DB7 
IGHV4-39*01  IGHD3-10*01,IGHD3-10*02,IGHD5-18*01  
IGHJ5*02 
2.7% (8/298) 
DB8 IGHV1-3*01 IGHD6-19*01  IGHJ4*02 2% (6/294) 
DB9 
IGHV4-39*02  IGHD1-1*01,IGHD1-14*01,IGHD1-20*01  
IGHJ2*01 
2.3% (7/298) 
DB10 IGHV3-21*01  IGHD3-10*01,IGHD3-10*02  IGHJ6*02 2.4% (7/295) 
 937 
 938 
 939 
 940 
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Table S2 List of anti-PvDBPII mAb binding properties, related to Figure 1 Association-rate (Kon), 941 
dissociation-rate (Koff) and affinity (KD) are shown. 942 
mAb Kon (M-1s-1) Koff (s-1) KD (M) 
DB1 1.88E+07 6.46E-03 3.44E−10 
DB2 9.02E+05 6.05E-04 2.35E−10 
DB3 2.98E+06 4.27E-04 2.07E−10 
DB4 1.30E+06 4.39E-04 3.37E−10 
DB5 2.33E+06 4.33E-04 2.86E−10 
DB6 8.65E+06 2.53E-04 2.92E−11 
DB7 1.72E+07 1.13E-04 6.55E−12 
DB8 1.73E+06 3.92E-04 2.27E−10 
DB9 1.79E+07 3.57E-04 2.00E−11 
DB10 1.06E+07 5.05E-04 4.78E−11 
  943 
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Table S4: Data collection and refinement statistics 944 
 945 
 946 
 PvDBP:DB9 
Data collection  
Space group P6222 
Cell dimensions  
    a, b, c (Å) 173.58, 173.58, 169.88 
α,β,γ (°) 90.0, 90.0, 120.0 
Wavelength 0.97625 
Resolution (Å) 84.94 – 3.04 (3.09 – 3.04) 
Total Observations 58086 (2896) 
Total Unique 29628 (1442) 
Rpim (%) 4.0 (46.9) 
CC1/2 0.999 (0.670) 
I/σ(I) 12.8 (1.2) 
Completeness (%) 100.0 (100.0) 
Multiplicity 19.6 (20.1) 
  
Refinement  
Number of reflections 30703 
Rwork / Rfree 17.7 / 22.0 
Number of residues  
    Protein 648 
R.m.s deviations  
    Bond lengths (Å) 0.01 
    Bond angles (°) 1.24 
Ramachandran plot  
    Favored (%) 95.0% 
    Allowed (%) 5.0% 
    Disallowed (%) 0.0% 
  
  
All structures were determined from one crystal. 947 
Values in parentheses are for highest-resolution shell.  948 
 949 
 950 
 951 
 952 
 953 
 954 
 955 
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Table S4: List of contacts between PvDBPII and DB9. 956 
 
PvDBP-
RII 
residue 
 
Group Fab Chain Residue Group Interaction 
K412 Side Chain Heavy Chain Y74 Side Chain Hydrogen bond 
D476 Side Chain Light Chain S75 Side Chain Hydrogen bond 
E484 Side Chain Heavy Chain E20 Main Chain Hydrogen bond 
E484 Side Chain Heavy Chain G45 Main Chain Hydrogen bond 
N486 Side Chain Heavy Chain R118 Side Chain Hydrogen bond 
E487 Side Chain Light Chain Y68 Side Chain Hydrogen bond 
E487 Side Chain Light Chain S75 Main Chain Hydrogen bond 
V488 Side Chain Light Chain Y68 Side Chain Hydrophobic 
V488 Side Chain Light Chain L74 Side Chain Hydrophobic 
N492 Side Chain Heavy Chain T121 Main Chain Hydrogen bond 
E493 Side Chain Heavy Chain T52 Side Chain Hydrogen bond 
R497 Side Chain Light Chain W51 Side Chain Cation-pi 
R497 Main Chain Heavy Chain T121 Side Chain Hydrogen bond 
R497 Side Chain Heavy Chain T121 Main Chain Hydrogen bond 
G499 Main Chain Heavy Chain T52 Main Chain Hydrogen bond 
A500 Main Chain Heavy Chain S51 Main Chain Hydrogen bond 
E503 Side Chain Heavy Chain Y54 Side Chain Hydrogen bond 
E503 Side Chain Heavy Chain Y79 Side Chain Hydrogen bond 
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Table S5: primers 957 
 958 
Primer number Primer sequence (5’ to 3’)  
1 ACAGGTGCCCACTCCCAGGTGCAG 
2 AAGGTGTCCAGTGTGARGTGCAG 
3 CCCAGATGGGTCCTGTCCCAGGTGCAG 
4 CAAGGAGTCTGTTCCGAGGTGCAG 
5 GGAAGGTGTGCACGCCGCTGGTC 
6 ATGAGGSTCCCYGCTCAGCTGCTGG 
7 CTCTTCCTCCTGCTACTCTGGCTCCCAG 
8 ATTTCTCTGTTGCTCTGGATCTCTG 
9 GTTTCTCGTAGTCTGCTTTGCTCA 
10 GGTCCTGGGCCCAGTCTGTGCTG 
11 GGTCCTGGGCCCAGTCTGCCCTG 
12 GCTCTGTGACCTCCTATGAGCTG 
13 GGTCTCTCTCSCAGCYTGTGCTG 
14 GTTCTTGGGCCAATTTTATGCTG 
15 GGTCCAATTCYCAGGCTGTGGTG 
16 GAGTGGATTCTCAGACTGTGGTG 
17 CACCAGTGTGGCCTTGTTGGCTTG 
18 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG 
19 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
20 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
21 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
22 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
23 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
24 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
25 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
26 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
27 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
28 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
29 GATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCAG 
30 GATGGGCCCTTGGTCGACGCTGAAGAGACGGTGACCATTG 
31 GATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCGTG 
32 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
33 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
34 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
35 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
36 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
37 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC 
38 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
39 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
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40 CTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
41 ATGGTGCAGCCACCGTACGTTTGATYTCCACCTTGGTC 
42 ATGGTGCAGCCACCGTACGTTTGATATCCACTTTGGTC 
43 ATGGTGCAGCCACCGTACGTTTAATCTCCAGTCGTGTC 
44 ATGGTGCAGCCACCGTACGTCTGATTTCCACCTTGGTC 
45 CTTTTTCTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
46 CTTTTTCTAGTAGCAACTGCAACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
47 CTTTTTCTAGTAGCAACTGCAACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
48 CTTTTTCTAGTAGCAACTGCAACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
49 CTTTTTCTAGTAGCAACTGCAACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
50 CTTTTTCTAGTAGCAACTGCAACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
51 GGCTTGAAGCTCCTCACTCGAGGGYGGGAACAGAGTG 
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